20 July 2023 (Thursday) - Oncology Central Update

 

The nice people at Oncology Central broke with tradition this month and rather than sending very technical scientific stuff which went over my head, they sent stuff about what I might be doing in ten years’ time.

Realistically I expect to be retired by then, but you never know…

Design of SERENA-6, a Phase III switch trial with camizestrant in ESR1-mutant breast cancer during first-line treatment   Future Oncology, our partner journal, has recently published a Clinical Trial Protocol, which details the design of the SERENA-6 breast cancer trial.

Latest news

How are patients being put first in a new era of ‘common sense oncology’?   A comment published in The Lancet Oncology calls for a recalibrated approach to oncology care, where patient needs are put to the forefront and decisions to pursue research options are not influenced by an organization's profit motive.

Everyone in the UK with symptoms of colorectal cancer set to receive an at-home test   NICE’s diagnostic advisory committee has recently recommended the use of quantitative fecal immunochemical tests for all individuals suspected of colorectal cancer.

Could lung cancer prognosis be predicted from a drop of blood?   A blood-based protein panel combined with a prediction model shows potential to lower lung cancer death rate(?) by identifying individuals who need CT screening.

Topics: Cancer biology and pathology | Clinical trials | Drug approvals | Drug development | Diagnostics | Epidemiology | Genetics and genomics | Immuno- oncology | Industry and business | Patient perspective | Personalized medicine | Preclinical research and trials | Prevention and screening | Targeted therapies |